IL153436A0 - Processes and intermediates for preparing retroviral protease inhibitors - Google Patents

Processes and intermediates for preparing retroviral protease inhibitors

Info

Publication number
IL153436A0
IL153436A0 IL15343601A IL15343601A IL153436A0 IL 153436 A0 IL153436 A0 IL 153436A0 IL 15343601 A IL15343601 A IL 15343601A IL 15343601 A IL15343601 A IL 15343601A IL 153436 A0 IL153436 A0 IL 153436A0
Authority
IL
Israel
Prior art keywords
intermediates
processes
protease inhibitors
retroviral protease
preparing retroviral
Prior art date
Application number
IL15343601A
Other languages
English (en)
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24614772&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL153436(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of IL153436A0 publication Critical patent/IL153436A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/06—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D239/08—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms directly attached in position 2
    • C07D239/10—Oxygen or sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • AIDS & HIV (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL15343601A 2000-08-31 2001-08-29 Processes and intermediates for preparing retroviral protease inhibitors IL153436A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65191900A 2000-08-31 2000-08-31
PCT/US2001/026898 WO2002018349A2 (en) 2000-08-31 2001-08-29 Process and intermediates for preparing retroviral protease inhibitors

Publications (1)

Publication Number Publication Date
IL153436A0 true IL153436A0 (en) 2003-07-06

Family

ID=24614772

Family Applications (1)

Application Number Title Priority Date Filing Date
IL15343601A IL153436A0 (en) 2000-08-31 2001-08-29 Processes and intermediates for preparing retroviral protease inhibitors

Country Status (16)

Country Link
EP (1) EP1313712B1 (de)
JP (1) JP5021141B2 (de)
KR (1) KR100806533B1 (de)
CN (1) CN1264823C (de)
AT (1) ATE361913T1 (de)
AU (1) AU2001286889A1 (de)
BR (1) BR0108146A (de)
CA (2) CA2731273C (de)
CY (1) CY1106738T1 (de)
DE (1) DE60128367T2 (de)
DK (1) DK1313712T3 (de)
ES (1) ES2284684T3 (de)
IL (1) IL153436A0 (de)
MX (1) MXPA03001751A (de)
PT (1) PT1313712E (de)
WO (1) WO2002018349A2 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE539074T1 (de) * 2003-12-11 2012-01-15 Abbott Lab Die hiv-protease hemmende verbindungen
CN100358521C (zh) * 2004-12-28 2008-01-02 哈尔滨欧替药业股份有限公司 一种双唑泰栓剂及其制备工艺
CN103910634B (zh) * 2012-12-29 2018-04-27 广东东阳光药业有限公司 西格列汀中间体的制备方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5914332A (en) * 1995-12-13 1999-06-22 Abbott Laboratories Retroviral protease inhibiting compounds

Also Published As

Publication number Publication date
CA2731273C (en) 2013-10-15
KR100806533B1 (ko) 2008-02-25
KR20030061787A (ko) 2003-07-22
CA2416955C (en) 2011-04-26
BR0108146A (pt) 2004-01-06
WO2002018349A2 (en) 2002-03-07
HK1057040A1 (en) 2004-03-12
PT1313712E (pt) 2007-07-25
EP1313712A2 (de) 2003-05-28
CA2731273A1 (en) 2002-03-07
CA2416955A1 (en) 2002-03-07
ATE361913T1 (de) 2007-06-15
CY1106738T1 (el) 2012-05-23
CN1449388A (zh) 2003-10-15
MXPA03001751A (es) 2003-09-10
WO2002018349A3 (en) 2002-05-10
DE60128367D1 (de) 2007-06-21
ES2284684T3 (es) 2007-11-16
CN1264823C (zh) 2006-07-19
DE60128367T2 (de) 2008-01-10
JP2004507528A (ja) 2004-03-11
EP1313712B1 (de) 2007-05-09
JP5021141B2 (ja) 2012-09-05
DK1313712T3 (da) 2007-09-10
AU2001286889A1 (en) 2002-03-13

Similar Documents

Publication Publication Date Title
AP2003002916A0 (en) HIV protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis.
IL138113A0 (en) Synthesis of epothilones, intermediates thereto and analogues thereof
MXPA03005219A (es) Peptidos diarilicos como inhibidores de ns3-serina proteasa en hepatitis de virus c.
IL149005A0 (en) Hexahydrofuro-2', 3-bifuran-3-yl-n-{3'(1, 3-benzodioxol-5-ylsulfonyl) (isobutyl) amino-1-benzyl-2-hydroxypropyl} carbamate as restroviral protease inhibitor
MY113489A (en) Reversible protease inhibitors
MXPA02009706A (es) Metodo para sintesis de perindopril y sus sales farmaceuticamente aceptables.
TWI268278B (en) 2,6-quinolinyl and 2,6-naphthyl derivatives, processes for preparing them and their uses
TW200517374A (en) Cyclohexanecarboxylic acids
BG104885A (en) Novel heterocyclically substituted amides with cysteine protease-inhibiting effect
AU8738401A (en) Novel kallikrein gene
MXPA04004805A (es) Peptido novedoso que tiene un efecto inhibidor de la enzima convertidora de angiotensina.
BR9813817A (pt) Análogos de hemiasterlina
NZ331875A (en) Asymmetric synthesis of R-alpha-propyl-piperonyl amine and its analogs
ATE433458T1 (de) Modulatoren von ship-1
AU7903400A (en) Selective inhibitors of the urokinase plasminogene activators
MXPA03001751A (es) Procesos e intermediarios para preparar los inhibidores de proteasa retroviral.
IL138127A0 (en) Process for the synthesis of hiv protease inhibitors
NO994135D0 (no) Kinoksalindioner
SE9800865D0 (sv) New Process
PL359727A1 (en) Crystalline pharmaceutical
MXPA03004534A (es) Compuestos novedosos para su uso como inhibidores de la proteasa del virus de inmunodeficiencia humana (vih).
SG145572A1 (en) Intermediates useful in the synthesis of hiv-protease inhibitors and methods for preparing the same
PL366625A1 (en) Hiv protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis
MX9700960A (es) Procedimientos e intermedios en la sintesis de 5-(3-[exobiciclo[2.2.i] hept-2-iloxi]-4-metoxifenil)-3,4,5,6-tetrahidropirimidin-2(ih)-ona.
SI1066276T1 (en) Process for the synthesis of hiv protease inhibitors

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed
KB Patent renewed